PMC:7787218 / 45-1211 JSON TXT

Annnotations TAB JSON ListView MergeView

Id	Subject	Object	Predicate	Lexical cue	hp_id
T1	280-284	Phenotype	denotes	pain	http://purl.obolibrary.org/obo/HP_0012531
T2	406-411	Phenotype	denotes	fever	http://purl.obolibrary.org/obo/HP_0001945
T3	413-420	Phenotype	denotes	fatigue	http://purl.obolibrary.org/obo/HP_0012378
T4	422-430	Phenotype	denotes	headache	http://purl.obolibrary.org/obo/HP_0002315
T5	447-457	Phenotype	denotes	joint pain	http://purl.obolibrary.org/obo/HP_0002829
T6	878-885	Phenotype	denotes	allergy	http://purl.obolibrary.org/obo/HP_0012393
T7	1043-1059	Phenotype	denotes	Hypersensitivity	http://purl.obolibrary.org/obo/HP_0041092

Id	Subject	Object	Predicate	Lexical cue	tao:has_database_id
17	83-130	Species	denotes	severe acute respiratory syndrome coronavirus 2	Tax:2697049
18	132-142	Species	denotes	SARS-CoV-2	Tax:2697049
19	699-711	Species	denotes	participants	Tax:9606
20	840-852	Species	denotes	participants	Tax:9606
21	64-73	Disease	denotes	infection	MESH:D007239
22	280-284	Disease	denotes	pain	MESH:D010146
23	286-293	Disease	denotes	redness	MESH:D003117
24	299-307	Disease	denotes	swelling	MESH:D004487
25	406-411	Disease	denotes	fever	MESH:D005334
26	413-420	Disease	denotes	fatigue	MESH:D005221
27	422-430	Disease	denotes	headache	MESH:D006261
28	447-457	Disease	denotes	joint pain	MESH:D018771
29	733-750	Disease	denotes	allergic reaction	MESH:D004342
30	878-885	Disease	denotes	allergy	MESH:D004342
31	1043-1059	Disease	denotes	Hypersensitivity	MESH:D004342

Id	Subject	Object	Predicate	Lexical cue
T2	0-379	Sentence	denotes	To date, the development of mRNA vaccines for the prevention of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a success story, with no serious concerns identified in the ongoing phase 3 clinical trials.1 Minor local side effects such as pain, redness, and swelling have been observed more frequently with the vaccines than with placebo.
T3	380-797	Sentence	denotes	Systemic symptoms such as fever, fatigue, headache, and muscle and joint pain have also been somewhat more common with the vaccines than with placebo, and most have occurred during the first 24 to 48 hours after vaccination.1 In the phase 1–3 clinical trials of the Pfizer–BioNTech and Moderna mRNA vaccines, potential participants with a history of an allergic reaction to any component of the vaccine were excluded.
T4	798-1166	Sentence	denotes	The Pfizer–BioNTech studies also excluded participants with a history of severe allergy associated with any vaccine (see the protocols of the two trials, available with the full text of the articles at NEJM.org, for full exclusion criteria).1,2 Hypersensitivity adverse events were equally represented in the placebo (normal saline) and vaccine groups in both trials.1